Abbott Laboratories (ABT)
Shares of ABT moved lower as broader market pressure outweighed several company-specific positives and neutral developments.
Entered a partnership to produce pharmaceuticals in Abu Dhabi, expanding manufacturing capacity and access to emerging markets.
Scheduled its second-quarter 2025 earnings call for July 17, offering investors an opportunity to assess upcoming financial results.
Featured in an NVST vs. ABT valuation comparison by analysts, highlighting relative metrics without altering consensus views.
A series of legal and political rulings involving Governor Abbott bear no direct impact on Abbott Laboratoriesâ€™ business operations.
ABT stock declined 2.7% to $133.67 in the last session, underperforming despite broader market gains.
Posted 3h ago
AI Generated. May Contain Errors.